David A. Siegel Dyne Therapeutics, Inc. Transaction History

Two Sigma Advisers, LP

$41.3 Billion
Q3 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 60,700 shares of DYN stock, worth $1.78 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

60,700

Previous 124,000 51.05%

Holding current value

$1.78 Million

Previous $4.38 Million 50.17%

% of portfolio

0.01%

Previous 0.01%

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$31.94 - $47.04 $2.02 Million - $2.98 Million	-63,300 Reduced 51.05%	60,700 $2.18 Million
Q2 2024 Aug 14, 2024	BUY	$23.65 - $35.63 $2.61 Million - $3.93 Million	110,400 Added 811.76%	124,000 $4.38 Million
Q1 2024 May 15, 2024	SELL	$13.06 - $29.18 $57,464 - $128,392	-4,400 Reduced 24.44%	13,600 $386,000
Q4 2023 Feb 14, 2024	SELL	$6.62 - $13.64 $222,432 - $458,304	-33,600 Reduced 65.12%	18,000 $239,000
Q3 2023 Nov 14, 2023	SELL	$8.6 - $12.18 $939,980 - $1.33 Million	-109,300 Reduced 67.93%	51,600 $462,000
Q2 2023 Aug 14, 2023	SELL	$8.53 - $14.28 $644,868 - $1.08 Million	-75,600 Reduced 31.97%	160,900 $1.81 Million
Q1 2023 May 15, 2023	BUY	$10.88 - $15.0 $1.41 Million - $1.94 Million	129,200 Added 120.41%	236,500 $2.72 Million
Q4 2022 Feb 14, 2023	BUY	$9.37 - $13.8 $630,601 - $928,740	67,300 Added 168.25%	107,300 $1.24 Million
Q3 2022 Nov 14, 2022	BUY	$7.2 - $15.17 $113,040 - $238,169	15,700 Added 64.61%	40,000 $508,000
Q2 2022 Aug 15, 2022	SELL	$4.36 - $10.5 $105,512 - $254,100	-24,200 Reduced 49.9%	24,300 $167,000
Q1 2022 May 16, 2022	SELL	$6.52 - $12.27 $9,128 - $17,178	-1,400 Reduced 2.81%	48,500 $468,000
Q4 2021 Feb 14, 2022	BUY	$11.89 - $16.07 $267,525 - $361,575	22,500 Added 82.12%	49,900 $593,000
Q3 2021 Nov 15, 2021	BUY	$15.6 - $21.46 $23,400 - $32,190	1,500 Added 5.79%	27,400 $445,000
Q2 2021 Aug 16, 2021	SELL	$15.94 - $22.33 $165,776 - $232,231	-10,400 Reduced 28.65%	25,900 $545,000
Q1 2021 May 17, 2021	BUY	$14.0 - $29.3 $166,600 - $348,670	11,900 Added 48.77%	36,300 $564,000
Q4 2020 Feb 16, 2021	BUY	$16.81 - $23.94 $410,163 - $584,136	24,400 New	24,400 $512,000

Others Institutions Holding DYN

# of Institutions

210

Shares Held

102M

Call Options Held

234K

Put Options Held

238K

View Full List

About Dyne Therapeutics, Inc.

Ticker DYN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,765,400
Market Cap $1.52B
Description
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...

More about DYN

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account